Flowers on a vine Flowers on a vine Flowers on a vine


Learn about REBYOTA and how it helps prevent the recurrence of C. diff infection.

REBYOTA is the first and only FDA approved microbiome-based treatment to prevent recurrent C. diff infection, after you’ve already taken antibiotics1

Learn more about REBYOTA—access Frequently Asked Questions here.

One dose one visit

What is Rebyota
Flowers on a vine

This is Freda’s Story

I just knew that if I had C. diff again, I wasn’t going to survive. But my C. diff didn’t come back after I had my treatment.

Watch Freda’s Story

Most common side effects may include stomach pain, diarrhea, bloating, gas, and nausea.

For more information, please talk to your doctor and see full Prescribing Information. Freda was compensated for her time. Individual results may vary.

Image of Freda, clinical study patient
Freda, Clinical Study Patient
Rebyota Patient Brochure

Learn more about C. diff infection and preventing its recurrence with REBYOTA.

Download Brochure

In a major clinical study with REBYOTA1,a:



success rate1,b



success rate1,b

Of those patients who saw success with REBYOTAb

~90% stayed free of C. diff at 6 months.2

Most common side effects may include stomach pain (8.9%), diarrhea (7.2%), bloating (3.9%), gas (3.3%), and nausea (3.3%).1
In clinical studies, there were no serious adverse events related to REBYOTA.1

aThe study was conducted in approximately 300 adult patients with recurrent C. diff infection for up to 8 weeks to find out how well REBYOTA
prevented recurrent C. diff infection. Patients in this study first completed treatment with antibiotics.1,2
bSuccess rate indicates no other recurrence of C. diff infection at 8 weeks.2

Flowers on a vine Flowers on a vine

If you’re ready to talk to a doctor, this customized discussion guide is a great way to prepare.

Sign up for more information

Receive additional information and resources to help you through your C. diff infection journey.

What’s your experience with C. diff infection?*(Required)

*Required field.



  1. REBYOTA. Prescribing Information. Parsippany, NJ: Ferring Pharmaceuticals Inc; 2022.
  2. Khanna S, Assi M, Lee C, et al. Efficacy and safety of RBX2660 in PUNCH CD3, a phase III, randomized, double blind, placebo controlled trial with a Bayesian primary analysis for the prevention of recurrent Clostridioides difficile infection. Drugs. 2022;82(15):1527-1538.

Please see Important Safety Information and full Prescribing Information


REBYOTA (fecal microbiota, live – jslm) is indicated for the prevention of recurrence of Clostridioides difficile (C. diff) infection in individuals
18 years of age and older, following antibiotic treatment for recurrent C. diff infection.
Limitation of Use
REBYOTA is not indicated for the treatment of C. diff infection.

Important Safety Information

  • You should not receive REBYOTA if you have a history of a severe allergic reaction (e.g., anaphylaxis) to REBYOTA or any of its components.
  • You should report to your doctor any infection you think you may have acquired after administration.
  • REBYOTA may contain food allergens.
  • Most common side effects may include stomach pain (8.9%), diarrhea (7.2%), bloating (3.9%), gas (3.3%), and nausea (3.3%).
  • REBYOTA has not been studied in patients below 18 years of age.
  • Clinical studies did not determine if adults 65 years of age and older responded differently than younger adults.

You are encouraged to report negative side effects of prescription drugs to FDA. Visit or call 1-800-332-1088.

Please click to see the full Prescribing Information

You are leaving

The link you have selected will direct you to a site or resource outside of our website.
Thank you.